RNS Number : 6689A
OptiBiotix Health PLC
24 September 2025

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Director/PDMR Shareholding

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, announces that the Company has been informed that Stephen O'Hara, a Director of the Company, made the following purchases of ordinary shares in the capital of the Company. Further details are set out in the Notification of Dealing Form below.

Director	*Purchase price (Aggregated)*	*Ordinary shares purchased*	*Resultant interest in ordinary shares*	*Resultant percentage of issued ordinary shares*
Stephen O'Hara	10.13 pence	195,238	10,408,224	10.08%

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman
Stephen O'Hara, Chief Executive

Cairn Financial Advisers LLP (NOMAD and Broker) Tel: 020 7213 0880
Liam Murray / Ludovico Lazzaretti / James Western

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

<table>
<tr><td colspan="3">Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</td></tr>
<tr><td>1</td><td colspan="2">Details of the person discharging managerial responsibilities/person closely associated</td></tr>
<tr><td>a.</td><td>Name</td><td>Stephen O'Hara</td></tr>
<tr><td>2</td><td>Reason for notification</td><td></td></tr>
<tr><td>a.</td><td>Position/Status</td><td>Director - Chief Executive Officer</td></tr>
<tr><td>b.</td><td>Initial notification/
Amendment</td><td>Initial Notification</td></tr>
<tr><td>3</td><td colspan="2">Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</td></tr>
<tr><td>a.</td><td>Name</td><td>OptiBiotix Health Plc</td></tr>
<tr><td>b.</td><td>LEI</td><td></td></tr>
<tr><td>4</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a.</td><td>Description of the financial instrument, type of instrument

Identification Code</td><td>Ordinary shares of 2p each

ISIN: GB00BP0RTP38</td></tr>
<tr><td>b.</td><td>Nature of the transaction</td><td>Purchase of ordinary shares</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td><table><tr><td>Price(s) per share</td><td>Volume(s)</td></tr><tr><td>9.77p</td><td>50,000</td></tr><tr><td>9.78p</td><td>50,000</td></tr></table></td></tr>
<tr><td>d.</td><td>Aggregated information
- Volume
- Price</td><td>
100,000 shares
9.77 pence per share</td></tr>
<tr><td>e.</td><td>Date of the transaction</td><td>22 September 2025</td></tr>
<tr><td>f.</td><td>Place of the transaction</td><td>London</td></tr>
</table>

<table>
<tr><td colspan="3">Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</td></tr>
<tr><td>1</td><td colspan="2">Details of the person discharging managerial responsibilities/person closely associated</td></tr>
<tr><td>a.</td><td>Name</td><td>Stephen O'Hara</td></tr>
<tr><td>2</td><td>Reason for notification</td><td></td></tr>
<tr><td>a.</td><td>Position/Status</td><td>Director - Chief Executive Officer</td></tr>
<tr><td>b.</td><td>Initial notification/
Amendment</td><td>Initial Notification</td></tr>
<tr><td>3</td><td colspan="2">Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</td></tr>
<tr><td>a.</td><td>Name</td><td>OptiBiotix Health Plc</td></tr>
<tr><td>b.</td><td>LEI</td><td></td></tr>
<tr><td>4</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a.</td><td>Description of the financial instrument, type of instrument

Identification Code</td><td>Ordinary shares of 2p each

ISIN: GB00BP0RTP38</td></tr>
<tr><td>b.</td><td>Nature of the transaction</td><td>Purchase of ordinary shares</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td><table><tr><td>Price(s) per share</td><td>Volume(s)</td></tr><tr><td>10.5p</td><td>47,619</td></tr><tr><td>10.5p</td><td>47,619</td></tr></table></td></tr>
<tr><td>d.</td><td>Aggregated information
- Volume
- Price</td><td>
95,238 shares
10.5 pence per share</td></tr>
<tr><td>e.</td><td>Date of the transaction</td><td>23 September 2025</td></tr>
<tr><td>f.</td><td>Place of the transaction</td><td>London</td></tr>
</table>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information

may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSEIFFLEISEEU